Amylyx Pharmaceuticals Inc (AMLX) — Cash Flow Reinvestment Rate

Latest as of December 2023: 1.57x

Amylyx Pharmaceuticals Inc (AMLX) has a Cash Flow Reinvestment Rate of 1.57x as of December 2023, reinvesting $21.28 Million (capex $356.00K plus investments $20.93 Million) from operating cash flow of $13.55 Million. Check AMLX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

1.57x
(Capex + Investments) / Operating CF

Total Reinvested

$21.28 Million
Capex + Investments

Operating Cash Flow

$13.55 Million
USD

Capital Expenditures

$356.00K
USD

Amylyx Pharmaceuticals Inc Cash Flow Reinvestment Rate (2023–2023)

Historical reinvestment intensity for Amylyx Pharmaceuticals Inc across 1 annual periods. Explore Amylyx Pharmaceuticals Inc debt service capacity to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for Amylyx Pharmaceuticals Inc (2023–2023)

Year-by-year capital reinvestment analysis for Amylyx Pharmaceuticals Inc. For live market cap and broader valuation context, see Amylyx Pharmaceuticals Inc (AMLX) market capitalisation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2023 13.28x $158.29 Million $11.92 Million $1.24 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow